Abbott Laboratories (ABT) Income Statement Analysis

See more : Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) Income Statement Analysis – Financial Results

Complete financial analysis of Abbott Laboratories (ABT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbott Laboratories, a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Abbott Laboratories (ABT)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.abbott.com

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	40.11B	43.65B	43.08B	34.61B	31.90B	30.58B	27.39B	20.85B	20.41B	20.25B	21.85B	39.87B	38.85B	35.17B	30.77B	29.53B	25.91B	22.48B	22.34B	19.68B	19.68B	17.68B	16.29B	13.75B	13.18B	12.48B	11.88B	11.01B	10.01B	9.16B	8.41B	7.85B	6.88B	6.16B	5.38B	4.94B	4.39B	3.81B	3.36B
Cost of Revenue	17.98B	19.14B	18.54B	15.00B	13.23B	12.71B	12.34B	9.02B	8.75B	9.22B	10.04B	15.12B	15.54B	14.67B	13.21B	12.61B	11.42B	9.82B	10.64B	8.88B	9.47B	8.51B	7.75B	6.24B	5.98B	5.39B	5.05B	4.73B	4.33B	3.99B	3.68B	3.08B	2.76B	2.55B	2.25B	2.08B	1.86B	1.67B	1.54B
Gross Profit	22.13B	24.51B	24.54B	19.61B	18.67B	17.87B	15.05B	11.83B	11.66B	11.03B	11.81B	24.75B	23.31B	20.50B	17.56B	16.92B	14.49B	12.66B	11.70B	10.80B	10.21B	9.18B	8.54B	7.51B	7.20B	7.08B	6.84B	6.28B	5.69B	5.16B	4.72B	4.77B	4.12B	3.60B	3.13B	2.85B	2.53B	2.14B	1.82B
Gross Profit Ratio	55.18%	56.15%	56.97%	56.65%	58.53%	58.45%	54.96%	56.73%	57.13%	54.47%	54.05%	62.08%	60.00%	58.30%	57.06%	57.29%	55.92%	56.33%	52.36%	54.86%	51.86%	51.90%	52.42%	54.61%	54.64%	56.77%	57.54%	57.03%	56.79%	56.38%	56.18%	60.81%	59.85%	58.53%	58.19%	57.82%	57.65%	56.17%	54.19%
Research & Development	2.74B	2.89B	2.74B	2.42B	2.44B	2.30B	2.24B	1.42B	1.41B	1.35B	1.45B	4.32B	4.80B	3.73B	2.74B	2.69B	2.51B	2.26B	1.82B	1.70B	1.73B	1.56B	1.58B	1.35B	1.19B	1.22B	1.30B	1.20B	1.07B	963.52M	880.97M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	9.74B	9.12B	6.67B	6.79B	6.53B	6.94B	12.06B	12.76B	10.38B	8.41B	8.44B	7.41B	6.35B	5.50B	4.92B	5.05B	3.98B	3.73B	2.89B	2.86B	2.74B	2.68B	2.46B	2.23B	2.05B	1.99B	2.82B	2.18B	1.84B	1.60B	1.48B	1.28B	1.06B	928.20M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-495.00K	-817.00K	-324.00K	96.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	10.95B	11.25B	11.32B	9.70B	9.77B	9.74B	9.12B	6.67B	6.79B	6.53B	6.94B	12.06B	12.76B	10.38B	8.41B	8.44B	7.41B	6.35B	5.50B	4.92B	5.05B	3.98B	3.73B	2.89B	2.86B	2.74B	2.68B	2.46B	2.23B	2.05B	1.99B	2.82B	2.18B	1.84B	1.60B	1.48B	1.28B	1.06B	928.20M
Other Expenses	1.97B	2.01B	2.05B	2.13B	1.94B	139.00M	1.25B	-945.00M	281.00M	-14.00M	32.00M	34.00M	-119.00M	62.01M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-138.51M	0.00	0.00	0.00	0.00	0.00	0.00	-70.00M	427.80M	379.00M	355.90M	307.30M	270.90M	243.70M	199.50M	155.80M
Operating Expenses	15.66B	16.15B	16.11B	14.25B	14.14B	14.22B	13.33B	8.64B	8.79B	8.43B	9.18B	16.38B	17.56B	14.10B	11.15B	11.12B	9.91B	8.60B	7.32B	6.62B	6.78B	5.54B	5.31B	4.11B	4.05B	3.97B	3.99B	3.66B	3.30B	3.02B	2.80B	3.25B	2.56B	2.20B	1.91B	1.75B	1.52B	1.26B	1.08B
Cost & Expenses	33.63B	35.29B	34.65B	29.25B	27.37B	26.93B	25.66B	17.67B	17.54B	17.65B	19.22B	31.50B	33.10B	28.77B	24.36B	23.74B	21.34B	18.42B	17.96B	15.50B	16.26B	14.05B	13.06B	10.35B	10.03B	9.36B	9.03B	8.40B	7.63B	7.01B	6.48B	6.33B	5.32B	4.75B	4.16B	3.84B	3.38B	2.93B	2.62B
Interest Income	385.00M	183.00M	43.00M	46.00M	94.00M	105.00M	124.00M	99.00M	105.00M	77.00M	67.00M	79.23M	85.20M	105.45M	137.78M	201.23M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	637.00M	375.00M	490.00M	500.00M	576.00M	721.00M	780.00M	332.00M	58.00M	73.00M	90.00M	513.00M	530.14M	553.14M	382.00M	528.47M	593.14M	292.35M	153.66M	149.09M	146.12M	205.22M	234.76B	23.22M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.24B	3.27B	3.54B	3.33B	3.01B	3.28B	3.02B	1.35B	601.00M	555.00M	791.00M	2.78B	3.04B	2.62B	2.09B	1.84B	1.85B	1.56B	1.36B	1.29B	1.27B	1.18B	1.17B	827.43M	828.01M	784.24M	727.75M	686.09M	566.42M	510.50M	484.08M	427.80M	379.00M	355.90M	307.30M	270.90M	243.70M	199.50M	155.80M
EBITDA	10.61B	12.38B	12.74B	8.79B	7.77B	7.12B	6.13B	3.07B	4.83B	4.22B	3.45B	3.50B	9.26B	9.14B	9.49B	8.22B	6.43B	4.25B	6.22B	5.61B	4.20B	4.30B	4.39B	3.40B	3.98B	3.90B	3.56B	3.30B	2.95B	2.65B	2.41B	1.95B	1.94B	1.76B	1.53B	1.37B	1.25B	1.08B	892.90M
EBITDA Ratio	26.44%	24.50%	24.95%	21.94%	20.87%	19.51%	18.08%	13.38%	18.37%	15.51%	15.80%	21.08%	15.08%	19.30%	20.82%	21.20%	25.41%	33.72%	23.92%	27.28%	21.54%	25.87%	33.77%	26.56%	27.68%	29.46%	28.54%	29.05%	29.16%	28.61%	27.38%	21.50%	27.41%	28.02%	27.53%	27.03%	28.27%	27.62%	24.92%
Operating Income	6.48B	8.36B	8.43B	5.36B	4.53B	3.65B	1.73B	3.19B	2.87B	2.60B	2.63B	8.09B	5.75B	6.09B	6.24B	5.69B	4.58B	2.04B	4.36B	3.90B	3.32B	3.53B	1.89B	3.40B	3.15B	3.12B	2.85B	2.62B	2.38B	2.14B	1.92B	1.53B	1.56B	1.41B	1.22B	1.10B	1.01B	878.60M	737.10M
Operating Income Ratio	16.15%	19.16%	19.56%	15.48%	14.21%	11.94%	6.30%	15.27%	14.05%	12.84%	12.03%	20.28%	14.81%	17.31%	20.27%	19.28%	17.67%	9.09%	19.53%	19.81%	16.88%	19.96%	11.63%	24.74%	23.90%	24.99%	23.99%	23.76%	23.80%	23.42%	22.88%	19.43%	22.64%	22.83%	22.70%	22.32%	22.92%	23.07%	21.94%
Total Other Income/Expenses	186.00M	-56.00M	-214.00M	-389.00M	-455.00M	-777.00M	667.00M	-1.61B	316.00M	-81.00M	-92.00M	-1.22B	-553.36M	-374.75M	958.03M	162.45M	-108.90M	234.15M	257.65M	227.28M	411.89M	143.27M	-10.88M	415.83M	247.53M	123.98M	84.17M	52.44M	12.42M	22.48M	19.26M	212.80M	-12.80M	-55.30M	-27.00M	-46.60M	-68.50M	-59.90M	-42.60M
Income Before Tax	6.66B	8.31B	8.21B	4.97B	4.08B	2.87B	2.23B	1.41B	3.18B	2.52B	2.52B	6.26B	5.20B	5.71B	7.19B	5.86B	4.47B	2.28B	4.62B	4.13B	3.73B	3.67B	1.88B	3.82B	3.40B	3.24B	2.95B	2.67B	2.40B	2.17B	1.94B	1.74B	1.54B	1.35B	1.19B	1.06B	937.20M	818.70M	694.50M
Income Before Tax Ratio	16.61%	19.03%	19.06%	14.36%	12.78%	9.40%	8.15%	6.78%	15.60%	12.44%	11.54%	15.71%	13.38%	16.25%	23.38%	19.83%	17.25%	10.13%	20.68%	20.96%	18.98%	20.77%	11.56%	27.76%	25.78%	25.97%	24.82%	24.24%	23.92%	23.66%	23.11%	22.14%	22.46%	21.93%	22.20%	21.38%	21.36%	21.50%	20.67%
Income Tax Expense	941.00M	1.37B	1.14B	497.00M	390.00M	539.00M	1.88B	350.00M	577.00M	797.00M	138.00M	300.00M	470.00M	1.09B	1.45B	1.12B	863.33M	559.62M	1.25B	949.76M	981.18M	879.71M	332.76M	1.03B	951.13M	907.37M	855.48M	787.52M	706.62M	650.01M	544.10M	499.70M	455.50M	385.00M	334.40M	303.40M	304.60M	278.20M	229.20M
Net Income	5.72B	6.93B	7.07B	4.50B	3.69B	2.37B	477.00M	1.40B	4.42B	2.28B	2.58B	5.96B	4.73B	4.63B	5.75B	4.88B	3.61B	1.72B	3.37B	3.24B	2.75B	2.79B	1.55B	2.79B	2.45B	2.33B	2.08B	1.88B	1.69B	1.52B	1.40B	1.24B	1.09B	965.80M	859.80M	752.00M	632.60M	540.50M	465.30M
Net Income Ratio	14.27%	15.88%	16.42%	12.99%	11.56%	7.74%	1.74%	6.71%	21.68%	11.28%	11.79%	14.95%	12.17%	13.15%	18.68%	16.53%	13.92%	7.64%	15.10%	16.44%	13.99%	15.80%	9.52%	20.27%	18.56%	18.71%	17.50%	17.09%	16.87%	16.56%	16.64%	15.78%	15.83%	15.68%	15.98%	15.23%	14.42%	14.20%	13.85%
EPS	3.30	3.94	3.97	2.52	2.07	1.35	0.27	0.95	3.00	1.51	1.66	3.78	3.01	2.99	3.72	3.16	2.34	1.12	2.17	2.07	1.76	1.79	1.00	1.80	1.59	1.52	1.35	1.21	1.06	0.93	0.84	0.74	0.64	0.56	0.49	0.42	0.35	0.29	0.25
EPS Diluted	3.27	3.91	3.94	2.50	2.06	1.34	0.27	0.94	2.94	1.50	1.64	3.75	3.01	2.97	3.70	3.13	2.31	1.12	2.16	2.06	1.75	1.78	0.99	1.78	1.57	1.49	1.33	1.19	1.06	0.93	0.84	0.74	0.64	0.56	0.49	0.42	0.35	0.29	0.25
Weighted Avg Shares Out	1.73B	1.75B	1.78B	1.77B	1.77B	1.76B	1.74B	1.47B	1.47B	1.51B	1.55B	1.58B	1.57B	1.55B	1.55B	1.54B	1.54B	1.53B	1.55B	1.56B	1.56B	1.56B	1.55B	1.55B	1.54B	1.54B	1.55B	1.56B	1.59B	1.62B	1.66B	1.67B	1.70B	1.72B	1.75B	1.79B	1.81B	1.86B	1.86B
Weighted Avg Shares Out (Dil)	1.75B	1.76B	1.79B	1.79B	1.78B	1.77B	1.75B	1.48B	1.51B	1.53B	1.57B	1.59B	1.57B	1.56B	1.56B	1.56B	1.56B	1.54B	1.56B	1.57B	1.57B	1.57B	1.57B	1.57B	1.56B	1.56B	1.58B	1.58B	1.59B	1.62B	1.66B	1.67B	1.70B	1.72B	1.75B	1.79B	1.81B	1.86B	1.86B

US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results

October 16, 2024benzinga.com

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 20 points on Wednesday.

Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates

October 16, 2024zacks.com

Abbott (ABT) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.14 per share a year ago.

Abbott's Growth and Dividends Make It a Smart Portfolio Pick

October 16, 2024marketbeat.com

There are many reasons to own Abbott Laboratories NYSE: ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the...

Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook

October 16, 2024marketwatch.com

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company's medical-devices business.

Abbott slightly raises profit forecast on strong medical device sales

October 16, 2024reuters.com

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.

Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

October 16, 2024prnewswire.com

Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices Continues to strengthen portfolio with steady...